BACKGROUND： Stereotactic injection （striatum or lateral ventricle） and vascular injection （ tail vein or carotid artery） are now often used in cellular therapy for cerebral infarction. Stereotactic injection can ...BACKGROUND： Stereotactic injection （striatum or lateral ventricle） and vascular injection （ tail vein or carotid artery） are now often used in cellular therapy for cerebral infarction. Stereotactic injection can accurately deliver cells to the infarct area, but requires a stereotactic device and causes secondary trauma; vascular injection is easy and better for host neurological deficit recovery, but can cause thrombosis. OBJECTIVE： To compare the therapeutic potential of adult bone marrow-derived mesenchymal stem cells （BMSCs） transplantation by intraperitoneal versus intravenous administration to cerebral ischemic rats. DESIGN, TIME AND SE＇B＇ING： A randomized controlled animal experiment was performed at the Cell Room and Pathology Laboratory, Brain Hospital Affiliated to Nanjing Medical University from November 2007 to September 2008. MATERIALS： BMSCs were derived from 20 healthy Sprague-Dawley rats aged 4-6 weeks. METHODS： Forty-five adult middle cerebral artery occlusion （MCAO） rats were randomly divided into control, intravenous and intraperitoneal injection groups, with 15 rats in each group. At 21 days after modeling, rats in the control group received 1 mL of 0.01 mol/L phosphate buffered saline via tail vein injection and each experimental rat received 4 x 106 BMSCs labeled by bromodeoxyuridine （BrdU） via intravenous or intraperitoneal injection. MAIN OUTCOME MEASURES： Angiogenin expression and survival of transplanted cells were measured by immunohistochemical staining of brain tissue in infarction hemisphere at 7, 14 or 21 days after BMSC transplantation. Co-expression of BrdU/microtubule-associated protein 2 or BrdU/glial fibrillary acidic protein was observed by double-labeled immunofluorescence of cerebral cortex. Evaluation of nerve function adhesion-removal test was performed on the 14 or 21 days after BMSCs treatment. using the neurological injury severity score and the 1st and 21st day before and after MCAO, and at 3, 7 RESULTS： Angiogenin-positive new vess展开更多
目的观察复方苦参注射液联合同期放化疗治疗局部晚期鼻咽癌的疗效及其对患者免疫功能的影响。方法将2012年6月至2015年6月在西安交通大学第二附属医院肿瘤科门诊诊治的82例局部晚期鼻咽癌患者按照随机数法分为观察组42例和对照组40例,...目的观察复方苦参注射液联合同期放化疗治疗局部晚期鼻咽癌的疗效及其对患者免疫功能的影响。方法将2012年6月至2015年6月在西安交通大学第二附属医院肿瘤科门诊诊治的82例局部晚期鼻咽癌患者按照随机数法分为观察组42例和对照组40例,对照组采用顺铂3周化疗方案联合同期调强放射治疗(IMRT),观察组在对照组治疗的基础上加用复方苦参注射液20 m L静脉滴注,1次/d,连续14 d,停药7 d为一个周期,连续治疗3个周期。治疗前1 d及结束后1周观察并比较两组患者各项细胞免疫指标(CD3+、CD4+、CD8+及CD4+/CD8+)的变化情况;两组患者治疗过程中骨髓抑制最高等级反应程度;治疗结束后3个月时两组治疗的近期效果。结果所有的患者均完成放疗计划。观察组患者治疗后的CD4+水平较治疗前升高[(42.93±10.78)%vs(36.00±10.21)%],CD8+降低[(24.42±9.79)%vs(29.73±8.25)%),CD4+/CD8+比值升高(2.10±1.32 vs 1.38±0.83),观察组治疗后的细胞免疫功能水平优于其治疗前水平,差异均有统计学意义(P<0.05);观察组患者治疗后的CD4+、CD4+/CD8+增加量高于对照组[(6.65±1.34)%vs(-5.09±1.38)%、(0.56±0.15)vs(-0.57±0.16)],CD8+降低量高于对照组(-3.86±1.51)%vs(7.03±1.54)%,观察组治疗结束后细胞免疫功能水平优于对照组治疗后水平,差异均有统计学意义(P<0.05);观察组骨髓抑制程度低于对照组,差异有统计学意义(P<0.05);两组患者的近期疗效比较差异无统计学意义(P>0.05)。结论复方苦参注射液虽未能提高局部晚期鼻咽癌同期放化疗近期疗效,但能有效激活患者的细胞免疫功能,减轻局部晚期鼻咽癌同期放化疗对骨髓的损伤,值得临床推广应用。展开更多
目的采用动物实验了解深度采集浓缩红细胞对于机体造血功能的作用。方法选取16只健康成年雄性山羊,随机分组法等分为深度采血(实验A)组:采集浓缩红细胞(150-250)mL/只;采集全血(对照B)组:常规采集全血150 mL/只。2组动物分别于采血前1 ...目的采用动物实验了解深度采集浓缩红细胞对于机体造血功能的作用。方法选取16只健康成年雄性山羊,随机分组法等分为深度采血(实验A)组:采集浓缩红细胞(150-250)mL/只;采集全血(对照B)组:常规采集全血150 mL/只。2组动物分别于采血前1 d与采血后1、3、7、14、21 d各抽取静脉血10 mL/只,检查血常规、铁代谢指标及EPO等,观察、比较2组动物各项指标的变化;同时于采血前1 d与采血后7、14、21 d做髂后上嵴骨髓穿刺术取骨髓涂片检查,观察、比较2组动物骨髓造血能力的变化。结果 A、B 2组动物采血后1、3、7、14、21 d的Hb(g/L)分别为:97.9±9.2 vs 107.1±8.5、95.8±6.5 vs 106.1±10.6(P<0.05)、97.9±8.4 vs 105.4±12.0、107.5±8.9 vs 109.8±12.0、112.5±8.1 vs 114.0±17.9,其中2组动物采血后1、3 d均明显低于采血前:97.9±9.2 vs 95.8±6.5 vs 105.5±11.8、107.1±8.5 vs 106.1±10.6 vs 112.4±11.7(P<0.05);2组动物采血前后铁代谢指标及EPO的变化无明显变化(P>0.05),骨髓细胞均为增生活跃。结论深度采血组动物造血启动速度、造血速度大大高于采集全血组动物。展开更多
基金the"135 Project"Medical Key Talent Foundation of Jiangsu Province
文摘BACKGROUND： Stereotactic injection （striatum or lateral ventricle） and vascular injection （ tail vein or carotid artery） are now often used in cellular therapy for cerebral infarction. Stereotactic injection can accurately deliver cells to the infarct area, but requires a stereotactic device and causes secondary trauma; vascular injection is easy and better for host neurological deficit recovery, but can cause thrombosis. OBJECTIVE： To compare the therapeutic potential of adult bone marrow-derived mesenchymal stem cells （BMSCs） transplantation by intraperitoneal versus intravenous administration to cerebral ischemic rats. DESIGN, TIME AND SE＇B＇ING： A randomized controlled animal experiment was performed at the Cell Room and Pathology Laboratory, Brain Hospital Affiliated to Nanjing Medical University from November 2007 to September 2008. MATERIALS： BMSCs were derived from 20 healthy Sprague-Dawley rats aged 4-6 weeks. METHODS： Forty-five adult middle cerebral artery occlusion （MCAO） rats were randomly divided into control, intravenous and intraperitoneal injection groups, with 15 rats in each group. At 21 days after modeling, rats in the control group received 1 mL of 0.01 mol/L phosphate buffered saline via tail vein injection and each experimental rat received 4 x 106 BMSCs labeled by bromodeoxyuridine （BrdU） via intravenous or intraperitoneal injection. MAIN OUTCOME MEASURES： Angiogenin expression and survival of transplanted cells were measured by immunohistochemical staining of brain tissue in infarction hemisphere at 7, 14 or 21 days after BMSC transplantation. Co-expression of BrdU/microtubule-associated protein 2 or BrdU/glial fibrillary acidic protein was observed by double-labeled immunofluorescence of cerebral cortex. Evaluation of nerve function adhesion-removal test was performed on the 14 or 21 days after BMSCs treatment. using the neurological injury severity score and the 1st and 21st day before and after MCAO, and at 3, 7 RESULTS： Angiogenin-positive new vess
文摘目的观察复方苦参注射液联合同期放化疗治疗局部晚期鼻咽癌的疗效及其对患者免疫功能的影响。方法将2012年6月至2015年6月在西安交通大学第二附属医院肿瘤科门诊诊治的82例局部晚期鼻咽癌患者按照随机数法分为观察组42例和对照组40例,对照组采用顺铂3周化疗方案联合同期调强放射治疗(IMRT),观察组在对照组治疗的基础上加用复方苦参注射液20 m L静脉滴注,1次/d,连续14 d,停药7 d为一个周期,连续治疗3个周期。治疗前1 d及结束后1周观察并比较两组患者各项细胞免疫指标(CD3+、CD4+、CD8+及CD4+/CD8+)的变化情况;两组患者治疗过程中骨髓抑制最高等级反应程度;治疗结束后3个月时两组治疗的近期效果。结果所有的患者均完成放疗计划。观察组患者治疗后的CD4+水平较治疗前升高[(42.93±10.78)%vs(36.00±10.21)%],CD8+降低[(24.42±9.79)%vs(29.73±8.25)%),CD4+/CD8+比值升高(2.10±1.32 vs 1.38±0.83),观察组治疗后的细胞免疫功能水平优于其治疗前水平,差异均有统计学意义(P<0.05);观察组患者治疗后的CD4+、CD4+/CD8+增加量高于对照组[(6.65±1.34)%vs(-5.09±1.38)%、(0.56±0.15)vs(-0.57±0.16)],CD8+降低量高于对照组(-3.86±1.51)%vs(7.03±1.54)%,观察组治疗结束后细胞免疫功能水平优于对照组治疗后水平,差异均有统计学意义(P<0.05);观察组骨髓抑制程度低于对照组,差异有统计学意义(P<0.05);两组患者的近期疗效比较差异无统计学意义(P>0.05)。结论复方苦参注射液虽未能提高局部晚期鼻咽癌同期放化疗近期疗效,但能有效激活患者的细胞免疫功能,减轻局部晚期鼻咽癌同期放化疗对骨髓的损伤,值得临床推广应用。
文摘目的采用动物实验了解深度采集浓缩红细胞对于机体造血功能的作用。方法选取16只健康成年雄性山羊,随机分组法等分为深度采血(实验A)组:采集浓缩红细胞(150-250)mL/只;采集全血(对照B)组:常规采集全血150 mL/只。2组动物分别于采血前1 d与采血后1、3、7、14、21 d各抽取静脉血10 mL/只,检查血常规、铁代谢指标及EPO等,观察、比较2组动物各项指标的变化;同时于采血前1 d与采血后7、14、21 d做髂后上嵴骨髓穿刺术取骨髓涂片检查,观察、比较2组动物骨髓造血能力的变化。结果 A、B 2组动物采血后1、3、7、14、21 d的Hb(g/L)分别为:97.9±9.2 vs 107.1±8.5、95.8±6.5 vs 106.1±10.6(P<0.05)、97.9±8.4 vs 105.4±12.0、107.5±8.9 vs 109.8±12.0、112.5±8.1 vs 114.0±17.9,其中2组动物采血后1、3 d均明显低于采血前:97.9±9.2 vs 95.8±6.5 vs 105.5±11.8、107.1±8.5 vs 106.1±10.6 vs 112.4±11.7(P<0.05);2组动物采血前后铁代谢指标及EPO的变化无明显变化(P>0.05),骨髓细胞均为增生活跃。结论深度采血组动物造血启动速度、造血速度大大高于采集全血组动物。
